ESC 365 - Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?

HFA Premium Access

Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?

Session: Pharmacology and pharmacotherapy

Topic: Antidiabetic Pharmacotherapy

Speaker: Mr O. Chebbo (Montpellier, FR)

Event: Heart Failure 2024

Congress Presentation

About the speaker

Mr Omar Chebbo

Montpellier (France)

0 follower

5 more presentations in this session

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report

Speaker: Doctor M. Feola (Mondovi, IT)

Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines

Speaker: Doctor E. Higgisson (Dublin, IE)

Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis

Speaker: Doctor E. Hasabo (Galway, IE)

Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials

Speaker: Mr G. Yeap (GB)

Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis

Speaker: Doctor E. Hasabo (Galway, IE)

Access the full session

Pharmacology and pharmacotherapy

Speakers: Mr O. Chebbo, Doctor M. Feola, Doctor E. Higgisson, Doctor E. Hasabo, Mr G. Yeap...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources